Paraneoplastic symptoms: Cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1820-1825

  Ding, Guan xiong ^a   Feng, Chen chen ^a   Song, Ning hong ^b   Fang, Zu jun ^a   Xia, Guo wei ^a   Jiang, Hao wen ^a   Hua, Li xin ^b   Ding, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Paraneoplastic syndrome; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ANAMNESIS; ANEMIA; ARTICLE; CACHEXIA; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HUMAN; HYPERCALCEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEUROMUSCULAR DISEASE; PARANEOPLASTIC SYNDROME; PHYSICAL EXAMINATION; POLYCYTHEMIA; PRIORITY JOURNAL; THROMBOCYTOSIS;

PARANEOPLASTIC SYNDROME; RENAL CELL CARCINOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CACHEXIA; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; POLYCYTHEMIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84886239711     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.03.021     Document Type: Article

References (35)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics. CA Cancer J Clin 2002, 52:23-47.
2. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. Pathology and genetics of tumours of the urinary system and male genital organs 2004, World Lyons Health Organization Classification of Tumors, IARC, p. 7.
3. Novick A.C., Campbell S.C. Renal tumours. Campbell's Urology 2002, p. 2672-731. W. B. Saunders, Philadelphia. P.C. Walsh, A.B. Retik, E.D. Vaughan (Eds.).
4. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med 1996, 335:865-875.
5. Lokich J.J., Harrison J.H. Renal cell carcinoma: Natural history and chemotherapeutic experience. J Urol 1975, 114:371-374.
6. Sacco E., Pinto F., Sasso F., et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int 2009, 83:1-11.
7. Kim H.L., Belldegrun A.S., Freitas D.G., et al. Paraneoplastic signs and symptoms of renal cell carcinoma: Implications for prognosis. J Urol 2003, 170:1742-1746.
8. Kaelin W.G. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol 2003, 14:2703-2711.
9. Ljungberg B., Cowan N.C., Hanbury D.C., et al. EAU guidelines on renal cell carcinoma: The 2010 update. Eur Urol 2010, 58:398-406.
10. Minardi D., Lucarini G., Filosa A., et al. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol 2008, 21:447-455.
11. Sobin L.H., Wittekind C.H. International Union against Cancer (UICC). TNM classification of malignant tumours, 6th ed 2002, Wiley-Liss, New York, p. 193-5.
12. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663.
13. Ding GX,Song NH, Feng CC, et al. Is there an association between advanced stage of renal cell carcinoma and paraneoplastic syndrome? Med Princ Pract 2012 Jan 6. [Epub ahead of print].
14. Palapattu G.S., Kristo B., Rajfer J. Paraneoplastic syndromes in urologic malignancy: The many faces of renal cell carcinoma. Rev Urol 2002, 4:163-170.
15. Papac R.J., Poo-Hwu W.J. Renal cell carcinoma: A paradigm of lanthanic disease. Am J Clin Oncol 1999, 22:223-231.
16. Koo A.S., Armstrong C., Bochner B., et al. Interleukin-6 and renal cell cancer: Production, regulation, and growth effects. Cancer Immunol Immunother 1992, 35:97-105.
17. Blay J.Y., Rossi J.F., Wijdenes J., et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997, 72:424-430.
18. Renal cancer collaborators. Interferon-α and survival in metastatic renal carcinoma: Early results of a randomized controlled trial. Medical Research Council renal cancer collaborators. Lancet 1999, 353:14-17. Medical Research Council.
19. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-&;α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
20. Coppin C., Porzsolt F., Awa A., et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005, 1:CD001425.
21. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21:3127-3132.
22. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005, 23:1028-1043.
23. Amato R.J. Renal cell carcinoma: Review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005, 16:7-15.
24. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
25. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
26. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326.
27. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
28. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
29. Ljungberg B., Hanbury D.C., Kuczyk M.A., et al. Guidelines on renal cell carcinoma 2010 . Accessed February 14, 2012. http://www.uroweb.org/gls/pdf/09_Renal_Cell_Carcinoma%202010.pdf.
30. Wiesener M.S., Seyfarth M., Warecke C., et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002, 99:3562-3565.
31. Mihael A., Politi E., Havranek E., et al. Prognostic significance of erythropoietin expression in human renal cell carcinoma. BJU Int 2007, 100:29l-24.
32. Er O., Coşkun H.S., Altinbaş M., et al. Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia. Urol Int 2001, 67:175-177.
33. Warren M.M., Utz D.C., Kelalis P.P. Concurrence of hypernephroma and hypercalcemia. Ann Surg 1971, 174:863-865.
34. Mundy G.R., Ibbotson K.J., D'Souza S.M., et al. The hypercalcemia of cancer. N Engl J Med 1984, 310:1718-1727.
35. Karaca H., Lale A., Dikilitas M., et al. Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: A case report and review of the literature. Med Oncol 2010, 27:1023-1026.